Anixa Biosciences Inc. has announced a significant milestone in its ovarian cancer CAR-T trial, completing the fourth cohort with promising safety and efficacy results, and has filed a $200 million mixed-securities shelf offering to fund ongoing cli…

Anixa Biosciences, Inc. is a pioneering biotech company making significant strides in cancer diagnostics and therapeutics, with a focus on innovation and patient care.

Anixa Biosciences, a biotech company focused on cancer diagnostics and therapeutics, has experienced significant stock fluctuations and financial metrics that warrant further analysis.

Anixa Biosciences, a biotechnology company focused on cancer diagnostics and therapeutics, has reported significant progress and resilience in the face of industry challenges, with a market capitalization of $83.7 million.